Adaptimmune logo

Adaptimmune

Designing and delivering cell therapies to transform the lives of people with cancer.

200 employees · est. 2008 · Abingdon, United Kingdom

VS
Olema Oncology logo

Olema Oncology

164 employees · est. 2007 · San Francisco, United States

Olema Oncology is the older company (2008 vs 2007).

Side-by-Side Comparison

Adaptimmune Olema Oncology
Founded
2008 2007 older
Headquarters
Abingdon, United Kingdom San Francisco, United States
Employees
200 164
Industry
Biopharma, Biotechnology, Health Care Biopharma, Biotechnology, Health Care
Funding Stage
Post Ipo Debt Post Ipo Equity
Total Funding
$499.50M $325.05M
Funding Rounds
9 5
Services
Development of T-cell therapies, Pipeline management of cell therapies, Sale and licensing of cell therapies, Biotechnological research, Clinical trials Not tracked yet
Target Customers
Cancer patients, Healthcare professionals, Biopharmaceutical companies, Medical researchers Not tracked yet
Taxonomy
Cell Therapy, Cancer Treatment, T Cell Therapies, Preclinical Research, Clinical Development, Translational Sciences, Autologous Manufacturing, Allogeneic Manufacturing, T Cell Receptor Proteins, Affinity T Cell Receptor, Immunotherapy, Infectious Disease Treatment, HIV Therapy, Corporate Operations Biopharmaceutical Company, Targeted Therapies, Women's Cancers, OP-1250, Estrogen Receptor Antagonist, Breast Cancer Treatment, Phase 1/2 Clinical Trial, Healthcare Investors, Pharmaceutical Development, Innovative Therapies, Clinical Research, Oncology, Biotech, Scientific Research
Website
adaptimmune.com olema.com
Adaptimmune logo

About Adaptimmune

Adaptimmune stands as a pioneering entity in the biopharmaceutical landscape, specializing in cell therapies designed to revolutionize cancer treatment. With its strong presence in four biotechnology hubs across the U.K. and U.S., the company showcases comprehensive competencies ranging from preclin...

Olema Oncology logo

About Olema Oncology

Olema Oncology is a biopharmaceutical company that focuses on developing innovative targeted therapies for women's cancers. Their lead program, OP-1250, is a potential best-in-class complete estrogen receptor antagonist (CERAN) designed to treat estrogen receptor-positive (ER+), human epidermal grow...

We will tell you when either one moves

BounceWatch watches Adaptimmune and Olema Oncology for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Adaptimmune and Olema Oncology — by email.

Frequently Asked Questions

Adaptimmune — Designing and delivering cell therapies to transform the lives of people with cancer.. Olema Oncology — . Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Adaptimmune has raised $499.50M while Olema Oncology has raised $325.05M.
Adaptimmune and Olema Oncology operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Adaptimmune with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Adaptimmune on 11 Mar 2026, and Olema Oncology on 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy